

October 15, 2015



# Cocrystal Pharma Announces Late Breaking Abstract at AASLD Liver Meeting

BOTHELL, WA and ATLANTA, GA -- (Marketwired) -- 10/15/15 -- **Cocrystal Pharma, Inc.** (OTCQB: COCP), a bio-pharmaceutical company dedicated to creating novel small molecules for viral infections and liver diseases, today announced that its late-breaking abstract was accepted for a poster presentation at The Liver Meeting, the annual meeting of the American Association of the Study of Liver Diseases (AASLD) in San Francisco, November 13-17. The abstract, entitled, "Preclinical characterization of CC-31244, a potent, pan-genotypic nonnucleoside NS5B polymerase inhibitor (NNI) for the treatment of chronic hepatitis C", will be presented by Dr. Sam Lee, President, on Monday the 16th at 12:30 pm. The abstract is available after October 20<sup>th</sup> at [www.aasld.org/](http://www.aasld.org/).

In the abstract, Cocrystal disclosed the genotype coverage, *in vitro* and preclinical properties of a novel NNI inhibitor, CC-31244

"We are encouraged by the CC-31244 preclinical profile and the opportunity to develop a novel, pan-genotypic NNI. Cocrystal is working to transition into a clinical company and excited about the numerous antiviral programs we are currently developing," said Dr. Douglas Mayers, Cocrystal Pharma Chief Medical Officer.

## **About Cocrystal Pharma**

Cocrystal is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Cocrystal employs unique technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. The company has identified promising, preclinical stage compounds for hepatitis infections, and analogs that are effective against noroviruses. Cocrystal has previously received strategic investments from Teva Pharmaceuticals, OPKO Health (NYSE: OPK), Dr. Raymond Schinazi, Brace Pharmaceutical, LLC, and The Frost Group. For further information about Cocrystal, please refer to [www.cocrystalpharma.com](http://www.cocrystalpharma.com), or connect with the Company on [Facebook](#), [LinkedIn](#), [Twitter](#) and [Google+](#).

Contact:  
MDM Worldwide  
David Zazoff  
212-643-0417

Source: Cocrystal Pharma, Inc.